These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 11366740)

  • 1. Class-sparing treatment therapies.
    Proj Inf Perspect; 1999 Apr; (27):5-6. PubMed ID: 11366740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nucleoside analogue-sparing strategy for the treatment of chronic HIV infection: potential interest and clinical experience.
    Joly V; Yeni P
    Antivir Ther; 2005; 10(1):29-40. PubMed ID: 15751761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NNRTI plus PI combinations in the perspective of nucleoside-sparing or nucleoside-failing antiretroviral regimens.
    Joly V; Descamps D; Yeni P
    AIDS Rev; 2002; 4(3):128-39. PubMed ID: 12416447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Choosing the right initial antiretroviral regimens.
    Norton M
    GMHC Treat Issues; 1999 Feb; 13(2):7-10. PubMed ID: 11366117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients.
    Youle M
    J Antimicrob Chemother; 2007 Dec; 60(6):1195-205. PubMed ID: 17890281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The psychology of compliance.
    Condor B
    Posit Aware; 1997; 8(2):18-20. PubMed ID: 11364453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overcoming resistance to existing therapies in HIV-infected patients: the role of new antiretroviral drugs.
    Perno CF; Moyle G; Tsoukas C; Ratanasuwan W; Gatell J; Schechter M
    J Med Virol; 2008 Apr; 80(4):565-76. PubMed ID: 18297706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategies for third line therapy.
    Proj Inf Perspect; 2002 Mar; (34):8-9. PubMed ID: 12038303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Options for first line therapy.
    Proj Inf Perspect; 1999 Apr; (27):7-8. PubMed ID: 11366741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiretroviral therapy and resistance to antiretroviral drugs.
    Lange JM; van Leeuwen R
    Ethiop Med J; 2002 Apr; 40 Suppl 1():51-75. PubMed ID: 12802831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Third line anti-HIV therapy options.
    Proj Inf Perspect; 2004 Jan; (37):19-21. PubMed ID: 15119286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. When should PIs be used?
    Slovick J
    Posit Living; 1999 Nov; 8(10):43-4. PubMed ID: 11367329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Term suppression of HIV infection: benefits and limitations of current treatment options.
    Sension MG
    J Assoc Nurses AIDS Care; 2007; 18(1 Suppl):S2-10. PubMed ID: 17275719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of number of mutations and of drug-class sparing on virological response to salvage genotype-guided antiretroviral therapy.
    Ciancio BC; Trotta MP; Lorenzini P; Forbici F; Visco-Comandini U; Gori C; Bonfigli S; Bellocchi MC; Sette P; D'Arrigo R; Tozzi V; Zaccarelli M; Boumis E; Narciso P; Perno CF; Antinori A
    Antivir Ther; 2003 Dec; 8(6):611-6. PubMed ID: 14760895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ritonavir-boosted protease inhibitor monotherapy for the treatment of HIV-1 infection.
    Sahali S; Chaix ML; Delfraissy JF; Ghosn J
    AIDS Rev; 2008; 10(1):4-14. PubMed ID: 18385776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Third line therapy options.
    Proj Inf Perspect; 1999 Apr; (27):9-11. PubMed ID: 11366743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Boosted protease inhibitor-based or nonnucleoside reverse transcriptase-based HAART: is there a best choice for antiretroviral-naive HIV-1 infected patients?
    Cuzin L; Allavena C; Morlat P; Dellamonica P
    AIDS Rev; 2008; 10(4):205-11. PubMed ID: 19092976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of antiretroviral triple combinations including the protease inhibitor nelfinavir in heavily pretreated children with HIV-1 infection.
    Hoffmann F; Funk M; Linde R; Notheis G; Petropoulou T; Eberle J; Gürtler L; Belohradsky BH; Wintergerst U
    Eur J Med Res; 2002 Jul; 7(7):330-4. PubMed ID: 12176683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.